| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.12 | 0.4 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.11 | 0.4 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.4 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |